RxDoctor Payments Data

Cynthia Ulm

Nurse Practitioner · Los Angeles, CANPI 1710143078

Payments from drug & device makers

$7,388in general payments, 2019–2025

Across 292 payments — averaging $25.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Amgen$790
  • AbbVie$591
  • AstraZeneca$553
  • GSK$520
  • Pfizer$416
  • plus $3K from 29 others

What the payments were for

  • Food & beverage$7,30999%
  • Education$791%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,388 in reported general payments places this provider in the 95th percentile of 6,779 nurse practitioner providers in California.

See all nurse practitioner providers in California

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide54$53,895
LinzessLinaclotide44$38,018
EliquisApixaban30$35,381
JardianceEmpagliflozin18$23,877
FarxigaDapagliflozin Propanediol15$21,725
JanuviaSitagliptin Phosphate15$21,504
RybelsusSemaglutide13$13,625
Ketoconazole23$2,077
Albuterol Sulfate HfaAlbuterol Sulfate70$1,784
Atorvastatin Calcium174$1,622
Gabapentin92$1,568
Levocetirizine Dihydrochloride58$1,342
Levothyroxine Sodium73$920
Naproxen11$915
Fluvoxamine Maleate11$832

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,285$67,52167 claims
AbbVieLinzess$591$38,01844 claims
PfizerEliquis$416$35,38130 claims
Boehringer IngelheimJardiance$127$23,87718 claims
AstraZenecaFarxiga$553$21,72515 claims
MerckJanuvia$46$21,50415 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,779 nurse practitioner providers in California.

Other nurse practitioner in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →